Clinical Trials Browser

Phase 1/2 × Urinary Bladder Neoplasms × tremelimumab × Clear all

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05120622 2023-10-31

Rideau

Phase 1/2 Withdrawn

Genitourinary

Urinary Bladder Neoplasms

NCT02643303 2022-12-02

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Phase 1/2 Completed

58 enrolled 24 charts

BreastDermatologicGenitourinaryHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Kidney Neoplasms, Melanoma, Prostatic Neoplasms, Sarcoma, Testicular Neoplasms, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Cutaneous

Clinical Trials

ADAPT-BLADDER

Rideau

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers